The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies that target both the NTD and the RBD
Amanat, F.; Thapa, M.; Lei, T.; Ahmed, S. M. S.; Adelsberg, D. C.; Carreno, J. M.; Strohmeier, S.; Schmitz, A. J.; Zafar, S.; Zhou, J. Q.; Rijnink, W.; Alshammary, H.; Borcherding, N.; Gonzalez Reiche, A.; Srivastava, K.; Sordillo, E. M.; van Bakel, H.; Turner, J. S.; Bajic, G.; Simon, V. M.; Ellebedy, A. H.; Krammer, F.
Show abstract
In this study we profiled vaccine-induced polyclonal antibodies as well as plasmablast derived mAbs from subjects who received SARS-CoV-2 spike mRNA vaccine. Polyclonal antibody responses in vaccinees were robust and comparable to or exceeded those seen after natural infection. However, that the ratio of binding to neutralizing antibodies after vaccination was greater than that after natural infection and, at the monoclonal level, we found that the majority of vaccine-induced antibodies did not have neutralizing activity. We also found a co-dominance of mAbs targeting the NTD and RBD of SARS-CoV-2 spike and an original antigenic-sin like backboost to seasonal human coronaviruses OC43 and HKU1 spike proteins. Neutralizing activity of NTD mAbs but not RBD mAbs against a clinical viral isolate carrying E484K as well as extensive changes in the NTD was abolished, suggesting that a proportion of vaccine induced RBD binding antibodies may provide substantial protection against viral variants carrying E484K.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants 98%
- Identification of antibodies targeting the H3N2 hemagglutinin receptor binding site following vaccination of humans 97%
- COVID-19 vaccination recruits and matures cross-reactive antibodies to conserved epitopes in endemic coronavirus Spike proteins 97%
Similar papers in this journal
- Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells 96%
- A SARS-CoV-2 Vaccination Strategy Focused on Population-Scale Immunity 95%
- Deep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccine 95%
Similar papers in this journal
- A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope 97%
- Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe disease 96%
- Vaccination reshapes the virus-specific T cell repertoire in unexposed adults 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.